Cargando…

Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial

INTRODUCTION: Experimental and clinical data demonstrate that skin diseases like psoriasis are affected by psychological factors and can be modulated by interventions other than conventional drug therapy. The expectation of patients towards the benefit of a forthcoming treatment as well as treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Hölsken, Stefanie, Krefting, Frederik, Schedlowski, Manfred, Sondermann, Wiebke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413966/
https://www.ncbi.nlm.nih.gov/pubmed/34475155
http://dx.doi.org/10.1136/bmjopen-2020-047099
_version_ 1783747743005540352
author Hölsken, Stefanie
Krefting, Frederik
Schedlowski, Manfred
Sondermann, Wiebke
author_facet Hölsken, Stefanie
Krefting, Frederik
Schedlowski, Manfred
Sondermann, Wiebke
author_sort Hölsken, Stefanie
collection PubMed
description INTRODUCTION: Experimental and clinical data demonstrate that skin diseases like psoriasis are affected by psychological factors and can be modulated by interventions other than conventional drug therapy. The expectation of patients towards the benefit of a forthcoming treatment as well as treatment pre-experiences have been demonstrated as crucial factors mediating placebo responses in inflammatory skin diseases. However, it is unknown whether and to what extent treatment outcomes of psoriasis patients under therapy with monoclonal antibodies like secukinumab can be experimentally modulated at subjective and physiological levels by modifying the expectation of patients via verbal instruction or prior experience. METHODS AND ANALYSIS: Treatment expectations will be modulated in patients with moderate-to-severe psoriasis undergoing treatment with the anti-interleukin-17A monoclonal antibody secukinumab. Patients with a Psoriasis Area and Severity Index (PASI) >12 will be randomly allocated to one of three groups (N=40 each). As a standard schedule, patients in the pharmacological control group (group 1) will be treated weekly with 300 mg secukinumab, while patients in groups 2 and 3 will receive only 75 mg secukinumab (75% dose reduction) during all treatment weeks. In addition to the injections, patients in group 3 will ingest a novel tasting drink, with a cover story explaining that previous studies showed additional beneficial effects of this combination (drug and drink). Patients will be assessed and treated at nine visits over a 16-week period, during which the severity of pain and itch symptoms, skin lesions and quality of life will be analysed with standardised questionnaires and the PASI. ETHICS AND DISSEMINATION: This study was approved by the Ethics committee of the Medical Faculty of the University Duisburg-Essen. Study outcomes will be published in peer-reviewed scientific journals.
format Online
Article
Text
id pubmed-8413966
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84139662021-09-22 Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial Hölsken, Stefanie Krefting, Frederik Schedlowski, Manfred Sondermann, Wiebke BMJ Open Dermatology INTRODUCTION: Experimental and clinical data demonstrate that skin diseases like psoriasis are affected by psychological factors and can be modulated by interventions other than conventional drug therapy. The expectation of patients towards the benefit of a forthcoming treatment as well as treatment pre-experiences have been demonstrated as crucial factors mediating placebo responses in inflammatory skin diseases. However, it is unknown whether and to what extent treatment outcomes of psoriasis patients under therapy with monoclonal antibodies like secukinumab can be experimentally modulated at subjective and physiological levels by modifying the expectation of patients via verbal instruction or prior experience. METHODS AND ANALYSIS: Treatment expectations will be modulated in patients with moderate-to-severe psoriasis undergoing treatment with the anti-interleukin-17A monoclonal antibody secukinumab. Patients with a Psoriasis Area and Severity Index (PASI) >12 will be randomly allocated to one of three groups (N=40 each). As a standard schedule, patients in the pharmacological control group (group 1) will be treated weekly with 300 mg secukinumab, while patients in groups 2 and 3 will receive only 75 mg secukinumab (75% dose reduction) during all treatment weeks. In addition to the injections, patients in group 3 will ingest a novel tasting drink, with a cover story explaining that previous studies showed additional beneficial effects of this combination (drug and drink). Patients will be assessed and treated at nine visits over a 16-week period, during which the severity of pain and itch symptoms, skin lesions and quality of life will be analysed with standardised questionnaires and the PASI. ETHICS AND DISSEMINATION: This study was approved by the Ethics committee of the Medical Faculty of the University Duisburg-Essen. Study outcomes will be published in peer-reviewed scientific journals. BMJ Publishing Group 2021-09-02 /pmc/articles/PMC8413966/ /pubmed/34475155 http://dx.doi.org/10.1136/bmjopen-2020-047099 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Dermatology
Hölsken, Stefanie
Krefting, Frederik
Schedlowski, Manfred
Sondermann, Wiebke
Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial
title Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial
title_full Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial
title_fullStr Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial
title_full_unstemmed Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial
title_short Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial
title_sort expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413966/
https://www.ncbi.nlm.nih.gov/pubmed/34475155
http://dx.doi.org/10.1136/bmjopen-2020-047099
work_keys_str_mv AT holskenstefanie expectationinducedenhancementofpainitchandqualityoflifeinpsoriasispatientsstudyprotocolofarandomisedcontrolledtrial
AT kreftingfrederik expectationinducedenhancementofpainitchandqualityoflifeinpsoriasispatientsstudyprotocolofarandomisedcontrolledtrial
AT schedlowskimanfred expectationinducedenhancementofpainitchandqualityoflifeinpsoriasispatientsstudyprotocolofarandomisedcontrolledtrial
AT sondermannwiebke expectationinducedenhancementofpainitchandqualityoflifeinpsoriasispatientsstudyprotocolofarandomisedcontrolledtrial